首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1425156

促血紅細胞生長素製劑市場－2024年至2029年預測

Erythropoietin Drugs Market - Forecasts from 2024 to 2029

出版日期: 2024年01月24日 | 出版商:

Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2022年促血紅細胞生長素藥品市值為138.03億美元。

促血紅細胞生長素製劑用於治療貧血，其特徵是紅血球數量減少。促血紅細胞生長素生成素刺激劑 (ESA) 是促促血紅細胞生長素的重組形式，透過細胞培養中的重組 DNA 技術以藥理方式產生。 ESA 包括紅血球生成素α、Darbepoetin和甲氧基聚乙二醇-紅血球生成素生成素BETA。 pO2 越低，EPO 的形成越明顯。當紅血球生成減弱時，最常使用 ESA。由於 EPO 可以增加肌肉的氧氣供應，因此有些運動員不當地使用 EPO 藥物來提高表現。然而，使用 EPO 製劑也會帶來嚴重的健康風險。

介紹

促血紅細胞生長素製劑市場是一個不斷成長的市場，涉及促血紅細胞生長素興奮劑（ESA）的生產和分銷。 ESA是促促血紅細胞生長素的重組製劑，透過細胞培養中的重組DNA技術在藥理上產生。該市場是由貧血發病率上升（特別是在人口老化中）以及對生物相似藥的需求不斷成長所推動的。市場可以按藥物類別、產品、應用和地區進行細分。亞太地區主導全球促血紅細胞生長素藥物市場。促血紅細胞生長素藥物市場的主要企業包括 Mayo Clinic、Weefsel Pharma、Trumac Healthcare 和 Incepta Pharmaceuticals Ltd。

促進因素

貧血發生率增加：促進因素：貧血發生率增加：虛弱的普遍存在，特別是在老年人群中，正在推動對促促血紅細胞生長素製劑的需求不斷增加。隨著世界各地社會中老年人比例的增加，採取有效的醫療干預措施來解決與老齡化相關的病理的必要性變得越來越明顯。促血紅細胞生長素是一種糖蛋白激素，在促進骨髓中紅血球的產生方面發揮著至關重要的作用。
生物相似藥需求不斷增加：促血紅細胞生長素產品的市場開拓呈現出生物相似藥發展的模式。這是因為需要降低醫療成本並使患者獲得這些藥物。
增加研發活動：促促血紅細胞生長素製劑領域創新研發活動的進展將推動新藥和治療方法的開發，並推動市場發展。
新興市場的採用率不斷提高：惡性生長、晚期腎病變（CKD）和愛滋病毒等永久性疾病在發展中業務領域的發病率呈上升趨勢，使得促促血紅細胞生長素素製劑在這些業務領域更受歡迎。我們正在推動對
專利保護：隨著許可證的獲得，促血紅細胞生長素（一種生技藥品）很可能在試驗期內主導市場。

主要企業提供的產品：

梅奧診所提供貧血治療，例如紅血球生成素素、Darbepoetin和甲氧基聚乙二醇-紅血球生成素生成素BETA。
Weefsel Pharma 的促血紅細胞生長素生成素注射是一種治療腎損傷或化療引起的貧血的藥物。

促血紅細胞生長素製劑市場中腎功能不全細分市場顯著成長：

由於末期腎功能衰竭治療、化療和抗逆轉錄病毒治療引起的貧血增加，預計促促血紅細胞生長素製劑市場在未來幾年將穩定成長。腎臟病細分市場（末期腎臟病和透析）在 2020 年佔據了很大佔有率，預計在預測期內將保持強勁的成長軌跡。癌症、慢性腎臟病(CKD) 和愛滋病毒等慢性疾病的盛行率不斷上升，刺激了對促血紅細胞生長素產品的需求。但隨著2018年促紅血球促血紅細胞生長素（EPO）生物相似藥登陸美國市場、Aranesp在美國的專利到期、價格下跌以及HIF脯氨醯羥化酶抑製劑的上市等，替代產品的開拓正在減緩促促血紅細胞生長素製劑市場的成長。由於促血紅細胞生長素產品（生物製藥）的專利仍然有效，預計促血紅細胞生長素產品領域在預測期內將保持其主導地位。

預計亞太地區將在促血紅細胞生長素製劑市場中佔據主要佔有率：

由於人口快速成長和癌症和慢性腎臟病（CKD）等慢性疾病的高盛行率，預計亞太地區將佔據促紅血球生成促血紅細胞生長素製劑市場的主要佔有率。該地區是促促血紅細胞生長素發展前景廣闊的市場，大部分促血紅細胞生長素原創企業都集中在亞太市場。印度和中國是主要的促血紅細胞生長素生物相似藥市場，該地區在生物相似藥產業中佔據最大佔有率，這些地區的主要製造商開拓新興國家生產生物相似藥。亞太地區的大多數生物相似藥製造商有能力以比創新產品低 25-40% 的價格推出促促血紅細胞生長素生物相似藥。由於促血紅細胞生長素素的開發較少，亞太和拉丁美洲地區為促血紅細胞生長素製造商提供了充滿希望的成長機會。

主要進展：

2020年6月，GlaxoSmithKline Plc公司（GSK）宣布推出口服缺氧誘導因子脯胺酸氧化酵素抑制劑（HIF-PHI）Dubroc（daprodustat），用於治療慢性腎臟病（CKD）相關貧血，並獲得藥品核准。在日本。

Erythropoietin drugs are used to treat anemia, which is a condition characterized by a low number of red blood cells. The erythropoietin stimulating agents (ESAs) are recombinant versions of erythropoietin produced pharmacologically via recombinant DNA technology in cell cultures. ESAs include epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin beta. The lower the pO2, the more prominent the creation of EPO. ESAs are for the most part shown in conditions where there is debilitated red platelet creation. Some athletes improperly use EPO drugs to boost their performance because EPO increases the availability of oxygen to their muscles. However, the use of EPO drugs can have serious health consequences as well.

Introduction:

The erythropoietin drugs market is a growing market that deals with the production and distribution of erythropoietin-stimulating agents (ESAs). ESAs are recombinant versions of erythropoietin produced pharmacologically via recombinant DNA technology in cell cultures. The market is driven by the increasing incidence of anaemia, particularly in the ageing population, and the growing demand for biosimilars. The market can be segmented based on drug class, product, application, and geography. Asia Pacific dominates the global erythropoietin drugs market. Key players operating in the erythropoietin drugs market include Mayo Clinic, Weefsel Pharma, Trumac Healthcare, and Incepta Pharmaceuticals Ltd.

Drivers:

Increasing incidence of anemia: The increasing prevalence of frailty, particularly among the aging demographic, has spurred a heightened demand for erythropoietin drugs. As societies around the world witness a growing proportion of elderly individuals, the need for effective medical interventions to address age-related conditions becomes more pronounced. Erythropoietin, a glycoprotein hormone, plays a pivotal role in stimulating the production of red blood cells in the bone marrow.
Growing demand for biosimilars: The market for erythropoietin drugs is seeing a developing pattern of biosimilars, which are less expensive options in contrast to marked drugs. This is driven by the need to decrease medical care costs and further develop admittance to these medications for patients.
Increasing research and development activities: The developing innovative work (Research and Development) exercises in the field of erythropoietin drugs are supposed to prompt the advancement of new medications and treatments, which will drive market development.
Growing adoption in emerging markets: The rising commonness of persistent sicknesses like malignant growth, ongoing kidney illness (CKD), and HIV in developing business sectors is driving the reception of erythropoietin drugs in these business sectors. This is supposed to help the market development before long.
Patents being protected: The biologics erythropoietin portion is supposed to rule the market during the gauge time frame, this is because of licenses being secured.

Products offered by key companies:

Mayo Clinic offers a range of erythropoietin drugs to treat anemia, including epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin beta. The clinic also provides comprehensive care for patients with anaemia, including diagnosis, treatment, and follow-up care.
Weefsel Pharma's erythropoietin injection is a treatment for anemia caused by kidney disorders and chemotherapy.

Prominent growth in the renal disorders segment within the erythropoietin drugs market:

The erythropoietin drug market is expected to grow steadily in the coming years, driven by the increasing prevalence of anemia caused by end-stage renal disease treatment, chemotherapy, and antiretroviral therapy. The kidney disorders segment (ESRD and dialysis) accounted for a significant share in 2020 and is expected to maintain a strong growth trajectory during the forecast period. The rising incidence of chronic diseases such as cancer, chronic kidney disease (CKD), and HIV is fueling the demand for erythropoietin drugs. However, the introduction of biosimilar erythropoietin (EPO) in the US market in 2018, the impending patent expiry of Aranesp in 2024 in the US, declining prices, and the development of alternative products such as HIF prolyl-hydroxylase inhibitors are moderating the growth of the erythropoietin drugs market. The biologics erythropoietin segment is expected to remain dominant during the forecast period, as patents for these drugs are still in effect.

The Asia Pacific region is expected to hold a significant share of the Erythropoietin drugs market:

The Asia Pacific region is expected to hold a significant share of the erythropoietin drugs market, driven by the rapidly increasing population and the high prevalence of chronic diseases such as cancer and chronic kidney disease (CKD). The region is a promising market for the growth of erythropoietin, and the majority of originator companies for erythropoietin are focusing on the Asia-Pacific market. India and China are major erythropoietin biosimilar markets, and the region demonstrates the largest share of the biosimilar industry, owing to the development of biosimilars by major manufacturers in these regions. The majority of biosimilar manufacturers in Asia-Pacific can afford to launch biosimilar versions of erythropoietin at 25-40% less price than innovator products. The Asia-Pacific and LAMEA regions offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin.

Key developments:

In June 2020, GlaxoSmithKline plc (GSK) secured Japanese regulatory approval for Duvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), in the treatment of anaemia associated with chronic kidney disease (CKD).

Segmentation

By Type

Biologics
Biosimilars

By Product

Erythropoietin
Darbepoetin-alfa

By Application

Cancer
Renal Diseases
Neurology
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. ERYTHROPOIETIN DRUGS MARKET, BY TYPE

5.1. Introduction
5.2. Biologics
5.3. Biosimilars

6. ERYTHROPOIETIN DRUGS MARKET, BY PRODUCT

6.1. Introduction
6.2. Erythropoietin
6.3. Darbepoetin-alfa

7. ERYTHROPOIETIN DRUGS MARKET, BY APPLICATION

7.1. Introduction
7.2. Cancer
7.3. Renal Diseases
7.4. Neurology
7.5. Others

8. ERYTHROPOIETIN DRUGS MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others